COMPANY INTELLIGENCEWhat the linked records show
MedtechLedger currently links 8 FDA records to the applicant name Ev3 Neurovascular. It includes 1 original PMA approval. 4 entries are PMA supplements. 3 entries are 30-day notices. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Jul 21, 2005 to Oct 14, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code MFE appears in 6 of the 8 linked filings. The collection spans 2 FDA product codes and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P030004, with 8 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 2 linked filings have a current plain-language explanation checked against the recorded FDA decision.
Applicant mailing address recorded by FDA: 9775 Toledo Way, Irvine, CA, 92618. Recorded on P030004/S039, decision dated Oct 14, 2026.
Device categories in this collection
Agent, Injectable, Embolic; Neurovascular Liquid Embolic Agent.
Changes described in PMA records
The FDA record for P030004/S039 shows an approval dated 2026-10-14 under the Normal 180 Day Track No User Fee, with the supplement reason listed as Postapproval Study Protocol. The changed item is the protocol for a Real-World Use Surveillance post-approval study for the Onyx Liquid Embolic System; the record states that this protocol was submitted to comply with conditions of approval in the earlier approval order for P030004/S035. The S039 supplement number marks it as a later supplement to the same PMA number, not a new approval of the whole system.
The decision covers the study protocol only. The record does not describe endpoints, patient population, sites, duration, or reporting requirements, and it does not report results or independent evidence of safety or clinical effectiveness. The applicant is Ev3 Neurovascular; specialty is Neurology; product code MFE, device category Agent, injectable, embolic. Those facts are absent from the supplied text and are not supplied here.
FDA approval-order wording
Approval of the protocol for the Real-World Use Surveillance post-approval study (PAS). The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P030004/S035.
Oct 14, 2026 · Normal 180 Day Track No User FeeFDA’s recorded scope: Approval to add the Onyx 12 LES to the Onyx LES product line for embolization of the middle meningeal artery (MMA) as an adjunct to surgery for the treatment of symptomatic subacute or chronic subdural hematoma (SDH).
Aug 5, 2026 · Normal 180 Day TrackFDA’s recorded scope: introduction of a new stir plate and modifications to processing parameters related to the stir plate settings used to manufacture the Onyx device
Jul 21, 2026 · 30-Day NoticeFDA’s recorded scope: approval of a new supplier for the dispenser coil component and its tubing supplier for the Apollo Onyx Delivery Micro Catheter
May 26, 2026 · 30-Day NoticeFDA’s recorded scope: Approval for changes to the mixing time, packaging configuration, and sterilization process for the Onyx Liquid Embolic System (LES).
Apr 29, 2026 · Real-Time ProcessSubsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.